Published in Aust N Z J Surg on February 01, 1981
Standardisation of spirometry. Eur Respir J (2005) 48.20
Interpretative strategies for lung function tests. Eur Respir J (2005) 21.50
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol (2000) 9.70
General considerations for lung function testing. Eur Respir J (2005) 7.99
Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J (2005) 7.58
Standardisation of the measurement of lung volumes. Eur Respir J (2005) 7.48
First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet (2002) 6.02
On the receiving end--patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol (1983) 4.35
Energy balance and colon cancer--beyond physical activity. Cancer Res (1997) 3.11
Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer (1998) 3.03
A snapshot of waiting times for cancer surgery provided by surgeons affiliated with regional cancer centres in Ontario. CMAJ (2001) 2.11
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet (2015) 2.05
A computerized diet history questionnaire for epidemiologic studies. J Am Diet Assoc (1994) 1.70
Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma. Eur J Cancer (1993) 1.64
Specifications for equipment used for infant pulmonary function testing. ERS/ATS Task Force on Standards for Infant Respiratory Function Testing. European Respiratory Society/ American Thoracic Society. Eur Respir J (2000) 1.57
Treatment of advanced squamous cell carcinoma of head and neck with cisplatin and continuous 96 hour infusion of 5-fluorouracil. Aust N Z J Med (1989) 1.38
Nasal decolonization of Staphylococcus aureus with mupirocin: strengths, weaknesses and future prospects. J Antimicrob Chemother (2009) 1.35
The Perceived Adjustment to Chronic Illness Scale (PACIS): a global indicator of coping for operable breast cancer patients in clinical trials. Swiss Group for Clinical Cancer Research (SAKK) and the International Breast Cancer Study Group (IBCSG). Support Care Cancer (1993) 1.23
On the receiving end--II. Linear analogue self-assessment (LASA) in evaluation of aspects of the quality of life of cancer patients receiving therapy. Eur J Cancer Clin Oncol (1983) 1.17
On the receiving end. IV: Validation of quality of life indicators. Ann Oncol (1991) 1.16
Improving informed consent: pilot of a decision aid for women invited to participate in a breast cancer prevention trial (IBIS-II DCIS). Health Expect (2008) 1.15
Randomized comparison of the effects of tamoxifen, megestrol acetate, or tamoxifen plus megestrol acetate on treatment response and survival in patients with metastatic breast cancer. Ann Oncol (1993) 1.14
A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer. Eur J Cancer (1995) 1.11
Diagnosis of copy number variation by Illumina next generation sequencing is comparable in performance to oligonucleotide array comparative genomic hybridisation. Genomics (2013) 1.09
Responsiveness of a single-item indicator versus a multi-item scale: assessment of emotional well-being in an international adjuvant breast cancer trial. Med Care (1996) 1.07
Measurement of respiratory system resistance by forced oscillation in normal children: a comparison with spirometric values. Pediatr Pulmonol (1991) 1.05
Quality of life measures for patients receiving adjuvant therapy for breast cancer: an international trial. The International Breast Cancer Study Group. Eur J Cancer (1992) 1.03
Definition of COPD: based on evidence or opinion? Eur Respir J (2008) 1.01
Subjective health estimations (SHE) in patients with advanced breast cancer: an adapted utility concept for clinical trials. Br J Cancer (1998) 0.97
Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group. Eur J Cancer (1998) 0.94
Cerebral metastases from malignant melanoma. Radiother Oncol (1992) 0.94
Promoting smoking cessation in general practice. BMJ (1993) 0.94
Effect of Mycobacterium tuberculosis chaperonins on bronchial eosinophilia and hyper-responsiveness in a murine model of allergic inflammation. Clin Exp Allergy (2004) 0.90
Menstrual cycle and timing of breast surgery in premenopausal node-positive breast cancer: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Ann Oncol (1997) 0.89
Aminoglutethimide in advanced prostatic carcinoma. Br J Urol (1987) 0.89
Plant foods and colon cancer: an assessment of specific foods and their related nutrients (United States). Cancer Causes Control (1997) 0.88
Evidence that treatment with vaccinia melanoma cell lysates (VMCL) may improve survival of patients with stage II melanoma. Treatment of stage II melanoma with viral lysates. Cancer Immunol Immunother (1987) 0.87
Deep Impact: observations from a worldwide Earth-based campaign. Science (2005) 0.87
Chemical synthesis of 10 kDa chaperonin. Biological activity suggests chaperonins do not require other molecular chaperones. FEBS Lett (1991) 0.87
Women gain weight 1 year after smoking cessation while dietary intake temporarily increases. J Am Diet Assoc (1996) 0.87
p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer. Ann Oncol (2008) 0.85
Propranolol in schizophrenia. I. Comparison of propranolol, chlorpromazine and placebo. Br J Psychiatry (1981) 0.85
Immune protection against experimental autoimmune encephalomyelitis: optimal conditions and analysis of mechanism. Cell Immunol (1974) 0.85
Timing of baseline quality of life assessment in an international adjuvant breast cancer trial: its effect on patient self-estimation. The International Breast Cancer Study Group. Ann Oncol (1994) 0.84
Dietary energy sources and colon cancer risk. Am J Epidemiol (1997) 0.84
Globin gene transcripts can utilize histone gene 3' end processing signals. Nucleic Acids Res (1986) 0.83
Chemotherapy for metastatic breast cancer--when is enough enough? Eur J Cancer (1997) 0.82
Prognostic value of performance status and quality-of-life scores during chemotherapy for advanced breast cancer. The Australian New Zealand Breast Cancer Trials Group. J Clin Oncol (1993) 0.81
Cystic fibrosis presenting as kwashiorkor in a Sri Lankan infant. Arch Dis Child (2003) 0.80
Phase-II study of recombinant alpha 2-interferon in advanced malignant melanoma. J Interferon Res (1986) 0.79
Phase I and pharmacokinetic study of tiazofurin (NSC 286193) administered by 5-day continuous infusion. Cancer Chemother Pharmacol (1986) 0.79
Standardisation of lung function testing: the authors' replies to readers' comments. Eur Respir J (2010) 0.77
Immunological effects of recombinant interferon alfa-2a in patients with disseminated melanoma. Cancer (1986) 0.77
Retreating recurrent breast cancer with the same CMF-containing regimen used as adjuvant therapy. The International Breast Cancer Study Group. Eur J Cancer (1997) 0.77
Quality of life assessment in the International Breast Cancer Study Group: past, present, and future. Recent Results Cancer Res (1998) 0.76
Metabolism of pyruvate by the early human embryo. Biol Reprod (1998) 0.76
Combined chemo-endocrine adjuvant therapy for patients with operable breast cancer: still a question? Cancer Treat Rev (1998) 0.76
Biparietal diameter at 11-13 weeks' gestation in fetuses with open spina bifida. Ultrasound Obstet Gynecol (2013) 0.76
Re: "Association of delayed conception with caffeine consumption". Am J Epidemiol (1994) 0.75
Who shall decide? Eur J Cancer (1995) 0.75
The quality of quality-of-life measurements. JAMA (1995) 0.75
Comparative study on the effects of recombinant alpha-2 interferon on immune function in patients with disseminated melanoma. J Biol Response Mod (1986) 0.75
Controversies in pediatric pulmonary medicine: infant pulmonary function tests. Am Rev Respir Dis (1988) 0.75
Benzo[a]pyrene site of contact mutagenicity in skin of Muta Mouse. Mutagenesis (1998) 0.75
Chemotherapy of advanced colorectal cancer. A randomized trial of sequential methotrexate and 5-fluorouracil. Am J Clin Oncol (1987) 0.75
Chemotherapy for head and neck cancer. Med J Aust (1983) 0.75
BCG immunotherapy. Med J Aust (1977) 0.75
Mitomycin and mitoxantrone in previously treated patients with advanced breast cancer. Cancer Treat Rep (1987) 0.75
Cyclophosphamide in pregnancy. Aust N Z J Obstet Gynaecol (1970) 0.75
Phase I study of epirubicin given on a weekly schedule. Cancer Treat Rep (1987) 0.75
Lesson learned from high-dose chemotherapy for high-risk breast cancer (What you see is what you mean). Ann Oncol (2004) 0.75
Variations in sensitivity, specificity, and predictive value of a dietary fat screener modified from Block et al. J Am Diet Assoc (1995) 0.75
Solar wind-induced atmospheric erosion at Mars: first results from ASPERA-3 on Mars Express. Science (2004) 0.75
What have we learned from meta-analysis? Med J Aust (1993) 0.75
Current status of immunotherapy. Drugs (1974) 0.75
Growth hormone response in very short children. Clin Invest Med (1991) 0.75
Acute leukaemia following chemotherapy including etoposide for testicular carcinoma. Aust N Z J Med (1993) 0.75
Pulmonary pseudotumours following chemotherapy for endodermal sinus tumour of the ovary. Aust N Z J Obstet Gynaecol (1982) 0.75
Mars environment and magnetic orbiter scientific and measurement objectives. Astrobiology (2009) 0.75
Single-agent versus combination antiemetic treatments in patients receiving cytotoxic chemotherapy. Med J Aust (1982) 0.75
Leslie Everton Hurley. Med J Aust (1967) 0.75
Alan Coates--CEO of the Australian Cancer Society. Interviewed by Sue Silver. Lancet Oncol (2000) 0.75
Monitoring distributional assumptions and early stopping for a prospective clinical trial using Monte Carlo simulation. Stat Med (1987) 0.75
The use of L-dopa and carbidopa in metastatic malignant melanoma. J Invest Dermatol (1991) 0.75
Sequential MTX and 5-FU: advance or myth? Eur J Cancer Clin Oncol (1986) 0.75
Current status of chemotherapy of breast cancer. Drugs (1984) 0.75
Advanced breast cancer: response to high dose oral medroxyprogesterone acetate. Aust N Z J Med (1984) 0.75
Lorazepam as an adjunct to antiemetic therapy with haloperidol in patients receiving cytotoxic chemotherapy. Aust N Z J Med (1983) 0.75
Hymenolepis diminuta: active transport of alpha-aminoisobutyric acid by cysticercoid larvae. Int J Parasitol (1973) 0.75